Ritlecitinib(Litfulo)

Ritlecitinib is an oral, highly selective inhibitor of JAK3/TEC family kinases and a novel targeted immunomodulatory agent.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Ritlecitinib Drug News

NICE UK Recommends Litfulo as First-Line Treatment for Severe Alopecia Areata

NICE Recommendation AnnouncementRecently, Litfulo (ritlecitinib) from Pfizer has been recommended by the UK National Institute for Health and Care Exc···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 71
FDA Approves Litfulo (ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

FDA Approval AnnouncementNEW YORK--(BUSINESS WIRE) June 23, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 72

Bigbear Pharmaceutical